Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-08-23
2005-08-23
Russel, Jeffrey Edwin (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200, C530S324000, C530S325000, C530S326000, C530S345000
Reexamination Certificate
active
06933279
ABSTRACT:
This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route.
REFERENCES:
patent: 3767040 (1973-10-01), Tushaus
patent: 4155913 (1979-05-01), Hellerbach et al.
patent: 4643988 (1987-02-01), Segrest et al.
patent: 5344822 (1994-09-01), Levine et al.
patent: 5721138 (1998-02-01), Lawn
patent: 5733549 (1998-03-01), Yamada et al.
patent: 5733879 (1998-03-01), Rosseneu et al.
patent: 5814467 (1998-09-01), Curtiss et al.
patent: 5854238 (1998-12-01), Kempen
patent: 6004925 (1999-12-01), Dasseux et al.
patent: 6037323 (2000-03-01), Dasseux et al.
patent: 6046166 (2000-04-01), Dasseux et al.
patent: 6086918 (2000-07-01), Stern et al.
patent: 6265377 (2001-07-01), Dasseux et al.
patent: 6287590 (2001-09-01), Dasseux et al.
patent: 6329341 (2001-12-01), Dasseux et al.
patent: 6376464 (2002-04-01), Dasseux et al.
patent: 6455088 (2002-09-01), Dasseux et al.
patent: 6518412 (2003-02-01), Dasseux et al.
patent: 6573239 (2003-06-01), Dasseux et al.
patent: 6602854 (2003-08-01), Dasseux et al.
patent: 6630450 (2003-10-01), Dasseux et al.
patent: 6664230 (2003-12-01), Fogelman et al.
patent: 6716816 (2004-04-01), Dasseux et al.
patent: 6734169 (2004-05-01), Dasseux et al.
patent: 6753313 (2004-06-01), Dasseux et al.
patent: 2001/0005714 (2001-06-01), Boffelli et al.
patent: 2003/0045460 (2003-03-01), Fogelman et al.
patent: 185761 (2004-04-01), None
patent: WO 97/36927 (1997-10-01), None
patent: WO 97/36927 (1997-10-01), None
patent: WO 99/47566 (1999-09-01), None
Anantharamaiah (1986) “Synthetic Peptide Analogs of Appolipoproteins.”Methods in Enzymology128:627-647.
Anantharamaiah and Garber (1996) “Chromatographic Methods for Quantitation of Apolipoprotein A-1.”Meth. Enzymol.263: 267-282.
Anantharamaiah et al. (1990) “Use of Synthetic Peptide Analogues to Localize Lecithin: Cholseterol Acyltransferase Activating Domain in Apolipoprotein A-1.”Arteriosclerosis10:95-105.
Anantharamaiah et al. (1993) “An Atlas of the Amphipathis Helical Domains of Human Exchangeable Plasma Apolipoproteins.”chapter 6: pp. 109-142 In:The Amphipathic Helix(Expand, R. M., ed), CRC Press, Boca Raton, FL.
Anantharamaiah et at. (1985) “Studies of Synthetic Peptide of the Amphipathic Helix.”The Journal of Biological Chemistry260:10248-10255.
Armstrong et al. (1993) D amino acid levels in human physiological fluids,Chirality,5: 375-378.
Badimon et al. (1990) “Regression of Atherosclerotic Lesions by High Density Lipoprotein Plasma Fraction in the Cholesterol-fed Rabbit.”J. Clinical Investigation85:1234-1241.
Boffeli et al. (1997) “The uptake of cholesterol at the small-intestinal brush border membrane is inhibited by apolipoproteins.” FEBS Letters, 411:7-11.
Borhani et al. (1999) “Crystal structure of truncated human apolipoprotein A-I suggests a lipid-bound conformation.”Proc. Natl. Acad. Sci. USA.94:12291-12296.
Brouillette and Anantharamaiah (1995) “Structural models of human apolipoprotein A-I.”Biochim. Biophys. Acta1256: 103-129.
Chung et al. (1985) “Studies of Synthetic Peptide Analogs of the Amphipathic Helix.”J. Biol. Chem.60(18): 10256-10262.
Davidson et al. (1994) “The Influence of Apolipoprotein Structure on the Efflux of Celluar Free Cholesterol to High Density Lipoprotein.”J. Biol. Chem.269(37): 22975-22982.
Dunlop and Neidle (1997) “The Orgion and Turnover of D-Serine in Brain.”Biochemical And Biophysical Research Communication235:26-30.
Ehara et al. (2001) “Elevated Levels of Oxidized Low Density Lipoprotein Show a Positive Relationship With the Severity of Acute Coronary Syndromes.”Circulation103:1955-1960.
Epand et al. (1987) “Studies Synthetic Peptide Analog of the Amphipathic Helix”J. Biol. Chem.262(19): 9389-9396.
Field et al. (2001) “Gene expression of sterol regulatory element-binding proteins in hamster small intestine.”Journal of Lipid Research42:1-9.
Fielding and Fielding (1995) “Molescular physiology of reverse cholesterol transport.”J. Lipid Res.36:211-228.
Fielding et al. (1972) “A Protein of Lecithin: Cholester Acyltransferase.”Biochem. Biophys. Res. Comm.46(2):1492-1498.
Garber et al. (1999) “Protection against Atherosclerosis in Mice by a Synthetic Class A Amphipathic Peptide Analog of Apolipoproteins A-I.”Circulation100:2838.
Garber et al. (1997)Circulation96-1-490.
Garber et al. (2001) “A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis.”Journal of Lipid Research42:545-552.
Garber et al. (1992) “Turnover of synthetic class A amphipathic peptide analogues of exchangeable apolipoproteins in rats. Correlation with physical properties.”Arteriosclerosis and Thrombosis,12(8): 886-894.
Glomset (1968) “The Plasma lecithin: cholesterol acytransferase reaction.”J. Lipid Res.9:155-167.
Gong et al. (1994) “Structural and functional properties of human and mouse apolipoprotein A-I.”Biochim. Biophys. Acta1213:335-342.
Hashimoto et al. (2000) “Improvement of intestinal absorption of peptides: absorption of B1-Phe monoglucosylated insulin to rat intestinal brush-border membrane vesicles.”J. Pharmaceutics&Therapeutics50(2):197-204.
Hayry et al. “Stabile D-peptide analog of insulin-like growth factor-1 inhibits smooth muscle cell proliferation after carotid ballooning injury in the rat.”FASEB J.9(13):1336-1344 (1995).
Johnson et al. (1991) “Cholesterol transport between cells and high-density lipoproteins.”Biochim. Biophys. Acta.1085: 273-298.
Jonas (1991) “Lecithin-cholesterol acyltransferase in the metabolism of high-density lipoproteins.”Biochim. Biophys. Acta1084: 205-220.
Jonas (2000) Lecithin cholesterol acyltransferase.Biochim. Biophys. Acta1529: 245-256.
Kigasawa et al. (1995) “Inhibition of corneal ulceration by tetrapeptidyl hydroxyamic acid.”Jap. J. Ophthalmology39(1):35-42.
Kreiger (1999) “Charting The Fate of the “Good Cholesterol”: Identification and Characterization of the High-Density Lipoprotein Receptor Sr-Bi.”Ann Rev. Biochem.68: 523-558.
Lancet (Sep. 25, 1999) New options developed for needle-free drug delivery.
Levi et al. (2000) “A retro-inverso minantibody with anti-HIV activity.”Aids Res.&Human Retruvirus16(1):59-65.
Man et al. (1987) D-aspartate in human brain.J Neurochem48:510-515.
Mishra et al. (1995) “Effect of the Arrangement of Tandem Repeating Units of Class A Amphipathic α-Helixes on Lipid Interaction.”J. Biol. Chem.270: 1602-1611.
Mishra et al. (1994) “Interaction of Synthetic Peptide Analogs of the Class A”,J. Biol. Chem.269: 7185-7191.
Mishra et al. (1998) Studies of Synthetic Peptides of Human Apolipoprotein A-I Containing Tandem Amphipathic α-HelixesBiochemistry37: 10313-10324.
Mor et al. (1992) Enter a new post-translational modification: D-amino acids in gene-encoded peptides,TIBS,17: 481-485.
Nagata et al. (1994) Distrubution of free D-serine in vertebrate brains,Brain Res.,634: 291-295.
Nagata et al. (1995) Free D-serine concentration in normal and Alzheimer human brain,Brain Res. Bull.,38(2): 181-183.
Navab et al. (2000) “Normal high density lipoprotein inhibits three steps in the formation of midly oxidized low density lipoprotein: step 1.”J. Lipid Res.41: 1481-1494.
Navab et al. (2000) “Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3.”J. Lipid Res.41: 1495-1508.
Nomoto et al. (1998) “Improved of intestinal abosrbtion of peptide drugs by Gyycosylation: Transport of Tetrapeptide by the Sodium Ion-Dependent D-Glucose Transporter.”J. Pharmaceutics Science87(3):326-332.
Ohtani et al. (1995) Age-related changes in D-aspartic acid o
Anantharamaiah Gattadahalli M.
Fogelman Alan M.
Navab Mohamad
Hunter Tom
Quine Intellectual Property Law Group P.C.
Russel Jeffrey Edwin
The Regents of the University of California
LandOfFree
Orally administered peptides to ameliorate atherosclerosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Orally administered peptides to ameliorate atherosclerosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Orally administered peptides to ameliorate atherosclerosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3494938